Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Cyclotek and Telix Pharmaceuticals Conclude Radiopharmaceutical Manufacturing Agreement for Australia and New Zealand

Posted on: 31 Jul 17

MELBOURNE, Australia, July 31, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix”) is pleased to announce the completion of a Master Services Agreement (“MSA”) with Cyclotek (Aust) Pty Ltd (“Cyclotek”). Under the agreement, Cyclotek will provide Telix with radiopharmaceutical manufacturing and distribution services for Telix’s pipeline of oncology products, for both clinical trial purposes and, where appropriate, prescriber exemption use.

Telix is developing a pipeline of therapeutic and diagnostic radiopharmaceutical products for use in a variety of oncology settings. As an Australian biotechnology company, Telix is committed to ensuring that engagement with leading Australian cancer hospitals are an integral part of the company’s clinical development activity, paving the way for domestic patient access in the future.1

Telix CEO Christian Behrenbruch stated, “We are very pleased to be working with Cyclotek to manufacture our products for the ANZ region. We’ve chosen to work with the Cyclotek team because of their experience, stellar track-record of delivering product and effective integration with both domestic and international clinical studies.”

Cyclotek Managing Director Greg Santamaria commented, “It’s great to see the emergence of a new radiopharmaceutical company with a late-stage product development pipeline that is committed to including Australian clinical sites in its development activities. We look forward to partnering with Telix for both clinical trials and ultimately the delivery of product to patients.”

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company headquartered in Melbourne, Australia. Telix is developing an advanced portfolio of clinical-stage products that address significant unmet medical needs in renal, prostate and brain (glioblastoma) cancer. Telix’s pipeline consists of “theranostic” radiopharmaceuticals, agents that can be used both diagnostically (via PET imaging) and therapeutically for patient benefit. Telix is an unlisted public company. For more information go to

About Cyclotek (Aust) Pty Ltd

Cyclotek has been the major supplier of Positron Emission Tomography (PET) radiopharmaceuticals since 2001. It currently operates four manufacturing facilities in Australia and New Zealand, and is rapidly expanding its facilities, and diversifying into manufacture of therapeutic radiopharmaceuticals. Cyclotek facilities are licenced by the Australian Therapeutic Goods Administration (TGA) to manufacture medicines according to the Code of Good Manufacturing Practice (GMP). For more information go to

1 Subject to applicable regulatory approvals or usage exemptions. Telix does not currently have regulatory authorization for the sale or use of any of its products in Australia or New Zealand.

CONTACT: Contact Telix Pharmaceuticals Limited Dr Christian Behrenbruch Tel.: +61 (0)406063247 Email: Cyclotek (Aust) Pty Ltd Mr Greg Santamaria Tel.: +61 418 554 353 Email: greg.santamaria@cyclotek.comGlobeNewswire

Last updated on: 31/07/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.